Synthesis of competences

Artificial intelligence in medicine.
New diagnostic methods.
Medical hybrid image.

SkinSENSE™

Unique technology of reading and interpreting skin allergy tests.

FaceCOV™

The world’s first medical standard remote temperature measurement system

InfraSKIN™

Detection of Melanoma and other malignant skin tumors.

model

T-

The latest information

Market debut of Milton Essex

12/12/2020

Market debut of Milton Essex. The listing of the Company will start on December 17, 2020. We invite you to our market debut. Press Release.

wektor

Read moreHide

Investment increase of the Company's share capital

13/12/2020

Management Board of Milton Essex S.A. informs that on July 20, 2020 it allocated 2,750,000 ordinary bearer series L shares. The increase of the Company’s share capital in connection with the issue was registered on August 5, 2020.

wektor

Read moreHide

Dofinansowanie projektu FaceCOV™

13/12/2020

Spółka podpisała z Narodowym Centrum Badań i Rozwoju umowy o dofinansowaniu projektu FaceCOV™, realizowanego w konsorcjum z Wojskową Akademią Techniczną. Przyznana kwota dofinansowania wynosi 6,9 mln zł.

wektor

Read moreHide

P-

Products

SkinSENSE™

The solution is to automate reading of skin allergic tests. Our SkinSENSE™ system with HYBRID II™ head for multispectral imaging introduces a new quality in allergology.

FaceCOV™

FaceCOV™ will probably be the world’s first registered medical device to allow remote temperature measurement from a distance.

InfraSKIN™

The InfraSKIN™ device will be strictly professional and will be aimed at dermatologists and oncologists. Its innovation will be based on LWIR band measurement, allowing to assess the rate of metabolism in the examined nevus – increased metabolism in the skin nevus indicates pathological cells.

A-

About the company

wektor

The development of ScanHybrid technology is possible thanks to the competence in Artificial Intelligence, advanced optoelectronics and clinical research. The company discounts over 20 years of research experience of its founders and scientific partners in the field of application of functional thermodynamic biomarkers in medical diagnostics.

Market leader

The company is a leader in the development of ultra accurate non-contact hybrid scanners for allergology and oncological dermatology. We conduct tests and research on the use of advanced optoelectronics.

Clinical trials

The Company conducts its own clinical trials. Recently, the Company has completed a 2-year program of clinical trials conducted in the Military Medical Institute in Warsaw, under the direction of Prof. Karina Jahnz-Różyk, within the Project POIR.01.01.01-00-0162/15.